Cardiovascular Risk Management – From Prevention to Treatment
Munich, Germany, 30-Aug-08
Tuomilehto, Prof. J., Helsinki, Finland
CV risk – an increasing global burden – how to find people at risk?
Lewanczuk, Dr. R., Alberta, Canada
Reducing the CV risk by anti-hypertensive combination strategies
Mancia, Prof. G., Milano, Italy
Optimal efficacy of nifedipine – a unique delivery system
Gaziano, Dr. J. M., Boston, United States
Anti-platelet therapy across the the range of CV risk
Gaziano, Dr. J. M., Boston, United States
Case studies
Standl, Prof. E., Munich, Germany
Hyperglycemia and CV risk – recommendations from current guidelines
Pan, Dr. C. Y., Beijing, China
Acarbose – a safe oral anti-diabetic agent providing CV benefits
Meredith, Dr. P. A., Glasgow, United Kingdom
Hypertension and the metabolic syndrome
Sierra de la, Prof. A., Barcelona, Spain
Treating hypertension in the metabolic syndrome – are all drugs the same?
Ruilope, Prof. L. M., Madrid, Spain
CV risk – suggestions for a comprehensive CV risk management?
Tendera, Prof. M., Katowice, Poland
Summary and closing remarks